Zhi Tong Cai Jing·2025-09-15 09:46Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its controlling shareholder, Shanghai Industrial (Group) Co., Ltd., through its wholly-owned subsidiary Shanghai International Investment Co., Ltd., is increasing its stake in the company, reflecting confidence in the company's future development [1] Group 1: Shareholding Increase - Shanghai International Investment Co., Ltd. increased its holdings by 100,000 H-shares on September 15, 2025, bringing its total holdings to 301 million H-shares, which represents 8.104% of the company's total share capital [1] - The controlling shareholder plans to further increase its stake by acquiring between 55 million to 74 million H-shares over the next 12 months, not exceeding 2% of the company's voting shares [1] - The share purchase will be conducted through the Hong Kong Stock Exchange via a centralized bidding method, with no fixed price range set for the acquisitions [1]